

William D Figg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5207826/publications.pdf>

Version: 2024-02-01

670
papers

35,247
citations

2538

96
h-index

5663

162
g-index

686
all docs

686
docs citations

686
times ranked

37093
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	0.8	1,960
2	Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999, 17, 3461-3467.	0.8	931
3	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5410-5417.	0.8	687
4	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551.	1.8	624
5	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 74-82.	0.8	571
6	Thalidomide. <i>Lancet, The</i> , 2004, 363, 1802-1811.	6.3	535
7	Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). <i>Clinical Cancer Research</i> , 2005, 11, 4136-4143.	3.2	437
8	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	0.6	428
9	Antibody-drug conjugates for cancer. <i>Lancet, The</i> , 2019, 394, 793-804.	6.3	425
10	Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents. <i>Journal of Clinical Oncology</i> , 2004, 22, 2489-2503.	0.8	423
11	Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 708-708.	0.8	413
12	Angiogenesis Inhibitors: Current Strategies and Future Prospects. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 222-243.	157.7	413
13	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. <i>Clinical Cancer Research</i> , 2002, 8, 718-28.	3.2	410
14	Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3912-3922.	0.8	389
15	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	13.9	360
16	Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2532-2539.	0.8	316
17	Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms. <i>Journal of Clinical Oncology</i> , 2001, 19, 2319-2333.	0.8	305
18	Cancer Survivorship Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. <i>Journal of the National Cancer Institute</i> , 2006, 98, 15-25.	3.0	295

#	ARTICLE	IF	CITATIONS
19	Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis <i>in vitro</i> and <i>in vivo</i> . <i>Clinical Cancer Research</i> , 2007, 13, 5183-5194.	3.2	295
20	Drug interactions in cancer therapy. <i>Nature Reviews Cancer</i> , 2006, 6, 546-558.	12.8	290
21	Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2593-2602.	0.8	288
22	Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent. <i>Biochemical Pharmacology</i> , 1998, 55, 1827-1834.	2.0	287
23	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , 2007, 109, 2781-2790.	0.6	279
24	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	3.4	266
25	Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives. <i>Current Neuropharmacology</i> , 2006, 4, 165-172.	1.4	251
26	Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. <i>Clinical Cancer Research</i> , 2011, 17, 907-917.	3.2	224
27	Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. <i>Molecular Pharmacology</i> , 2005, 68, 917-932.	1.0	223
28	Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8573-8578.	3.3	220
29	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 997-1008.	1.1	215
30	Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. <i>Clinical Cancer Research</i> , 2006, 12, 5777-5785.	3.2	214
31	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202.	0.8	209
32	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003, 6, 71-84.	6.5	207
33	Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and <i>nan</i> -Paclitaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4200-4205.	3.2	204
34	Validation of Analytic Methods for Biomarkers Used in Drug Development. <i>Clinical Cancer Research</i> , 2008, 14, 5967-5976.	3.2	202
35	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. <i>Cancer Biology and Therapy</i> , 2005, 4, 815-818.	1.5	200
36	A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer. <i>Journal of Experimental Therapeutics and Oncology</i> , 2002, 2, 325-332.	0.5	189

#	ARTICLE	IF	CITATIONS
37	Scientific Collaboration Results in Higher Citation Rates of Published Articles. <i>Pharmacotherapy</i> , 2006, 26, 759-767.	1.2	187
38	Effect of <i>SLCO1B3</i> Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3312-3318.	3.2	175
39	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 209-214.	3.2	174
40	Pharmacogenetics of irinotecan metabolism and transport: An update. <i>Toxicology in Vitro</i> , 2006, 20, 163-175.	1.1	165
41	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. <i>Blood</i> , 2011, 117, 4787-4795.	0.6	165
42	Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2003, 21, 2299-2304.	0.8	164
43	Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy. <i>Clinical Cancer Research</i> , 2005, 11, 6823-6834.	3.2	161
44	Effect of ABCG2 genotype on the oral bioavailability of topotecan. <i>Cancer Biology and Therapy</i> , 2005, 4, 650-653.	1.5	161
45	Phase IIb Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju089.	3.0	161
46	A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4820-4829.	3.2	160
47	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2496-2508.	1.9	157
48	Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1083-91.	3.3	156
49	<i>SLCO2B1</i> and <i>SLCO1B3</i> May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2565-2573.	0.8	153
50	A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2344-2351.	3.2	151
51	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. <i>European Journal of Cancer</i> , 2006, 42, 2893-2896.	1.3	150
52	Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2807-2813.	1.1	150
53	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 569-580.	3.2	149
54	Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1 α (HIF-1 α) and p300 by a Zinc Ejection Mechanism. <i>Journal of Biological Chemistry</i> , 2009, 284, 26831-26838.	1.6	148

#	ARTICLE	IF	CITATIONS
55	Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 584-592.	0.8	142
56	Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention. <i>Molecular Cancer Research</i> , 2006, 4, 135-150.	1.5	139
57	Coevolution of Prostate Cancer and Bone Stroma in Three-Dimensional Coculture: Implications for Cancer Growth and Metastasis. <i>Cancer Research</i> , 2008, 68, 9996-10003.	0.4	137
58	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1389-1395.	0.8	137
59	Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2070-2076.	0.8	136
60	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. <i>Cancer Biology and Therapy</i> , 2006, 5, 22-27.	1.5	135
61	Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1411-1416.	3.2	135
62	Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 153-159.	0.8	134
63	Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. <i>Drug Resistance Updates</i> , 2004, 7, 195-208.	6.5	132
64	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 1-8.	0.7	130
65	<i>ABCB1</i> Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4543-4549.	3.2	127
66	Multiparametric MRI in prostate cancer management. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 346-353.	12.5	127
67	Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 429-445.	1.5	126
68	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 192-201.	2.3	126
69	Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms. <i>Journal of Clinical Oncology</i> , 2002, 20, 4074-4082.	0.8	125
70	Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development. <i>Annals of Pharmacotherapy</i> , 2002, 36, 905-911.	0.9	125
71	TNP-470: an angiogenesis inhibitor in clinical development for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1383-1396.	1.9	123
72	A Working Group Classification of Focal Prostate Atrophy Lesions. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1281-1291.	2.1	123

#	ARTICLE	IF	CITATIONS
73	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 6831-6839.	3.2	123
74	Thalidomide metabolism by the CYP2C subfamily. <i>Clinical Cancer Research</i> , 2002, 8, 1964-73.	3.2	123
75	Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2007, 13, 5411-5417.	3.2	122
76	Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. <i>Journal of Urology</i> , 2008, 179, 2181-2186.	0.2	122
77	The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing. <i>Journal of Surgical Research</i> , 2000, 91, 26-31.	0.8	121
78	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. <i>European Urology</i> , 2008, 54, 1089-1096.	0.9	121
79	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2002, 8, 963-70.	3.2	120
80	Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin. <i>Clinical Cancer Research</i> , 2008, 14, 188-198.	3.2	119
81	Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. <i>Cancer Investigation</i> , 2009, 27, 221-226.	0.6	115
82	Phase I study of phenylacetate administered twice daily to patients with cancer. <i>Cancer</i> , 1995, 75, 2932-2938.	2.0	114
83	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. <i>Pharmacogenomics</i> , 2005, 6, 115-138.	0.6	114
84	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 294-305.	1.1	114
85	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1585-1592.	3.0	113
86	Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 3465-3474.	0.8	112
87	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009, 103, 1636-1640.	1.3	112
88	Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 854-860.	1.0	107
89	Modulation of cytochrome P450 activity: implications for cancer therapy. <i>Lancet Oncology</i> , The, 2005, 6, 780-789.	5.1	107
90	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021, 39, 566-579.e7.	7.7	107

#	ARTICLE	IF	CITATIONS
91	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. <i>Seminars in Oncology</i> , 2001, 28, 62-66.	0.8	107
92	Using Epigenetic Therapy to Overcome Chemotherapy Resistance. <i>Anticancer Research</i> , 2016, 36, 1-4.	0.5	105
93	Pharmacokinetics of thalidomide in an elderly prostate cancer population. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 121-125.	1.6	104
94	COVID-19 Clinical Diagnostics and Testing Technology. <i>Pharmacotherapy</i> , 2020, 40, 857-868.	1.2	104
95	Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. <i>Molecular Biotechnology</i> , 2010, 44, 152-167.	1.3	103
96	Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. <i>Clinical Cancer Research</i> , 2012, 18, 2099-2107.	3.2	103
97	A retrospective study of the time to clinical endpoints for advanced prostate cancer. <i>BJU International</i> , 2005, 96, 985-989.	1.3	102
98	Racial Variation in CAG Repeat Lengths Within the Androgen Receptor Gene Among Prostate Cancer Patients of Lower Socioeconomic Status. <i>Journal of Clinical Oncology</i> , 2002, 20, 3599-3604.	0.8	100
99	Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 α in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 5123-5131.	3.2	100
100	Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 394-403.	1.0	99
101	A phase II study of perfosine in androgen independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 1133-1137.	1.5	98
102	Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers. <i>PLoS ONE</i> , 2011, 6, e14504.	1.1	98
103	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 599-608.	2.0	97
104	Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. <i>Journal of Clinical Oncology</i> , 2001, 19, 832-842.	0.8	95
105	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 95.	3.5	94
106	Endothelial Monocyte Activating Polypeptide II Induces Endothelial Cell Apoptosis and May Inhibit Tumor Angiogenesis. <i>Microvascular Research</i> , 2000, 60, 70-80.	1.1	91
107	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 4125-4131.	0.8	91
108	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , 2018, 9, 2705.	5.8	91

#	ARTICLE	IF	CITATIONS
109	CYP2D6 polymorphisms and the impact on tamoxifen therapy. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2224-2231.	1.6	89
110	Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression. <i>PLoS ONE</i> , 2011, 6, e20372.	1.1	89
111	Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. <i>Urology</i> , 1998, 52, 252-256.	0.5	88
112	A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. , 2019, 7, 197.		88
113	Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. <i>American Journal of Medicine</i> , 1995, 98, 412-414.	0.6	87
114	Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor Progression and Therapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 499-506.	0.8	86
115	Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. <i>Investigational New Drugs</i> , 2002, 20, 183-194.	1.2	84
116	Endostatin Inhibits Microvessel Formation in the ex Vivo Rat Aortic Ring Angiogenesis Assay. <i>Biochemical and Biophysical Research Communications</i> , 2000, 268, 183-191.	1.0	83
117	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2014, 20, 5392-5402.	3.2	83
118	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , 2019, 25, 4945-4954.	3.2	82
119	Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, S54-S59.	1.1	81
120	Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications. <i>Current Drug Metabolism</i> , 2006, 7, 677-685.	0.7	80
121	Relationship of systemic exposure to unbound docetaxel and neutropenia. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 43-53.	2.3	79
122	Association of the <i>CYP1B1*3</i> allele with survival in patients with prostate cancer receiving docetaxel. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 19-26.	1.9	79
123	Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 4356-4363.	0.8	78
124	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
125	Pharmacodynamic markers and clinical results from the phase 2 study of the <i>SMAC</i> mimetic birinapant in women with relapsed platinum-resistant or refractory epithelial ovarian cancer. <i>Cancer</i> , 2016, 122, 588-597.	2.0	77
126	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060.	3.6	77

#	ARTICLE	IF	CITATIONS
127	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valsopodar). <i>Cancer</i> , 2001, 92, 1577-1590.	2.0	76
128	Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. <i>Pharmacogenomics</i> , 2010, 11, 89-103.	0.6	76
129	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
130	Polymorphism in the hypoxia-inducible factor 1 α gene may confer susceptibility to androgen-independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 1222-1225.	1.5	74
131	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 256-267.	1.2	74
132	Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1 α /p300 complex in a preclinical model of prostate cancer. <i>Molecular Cancer</i> , 2014, 13, 91.	7.9	73
133	Influence of Garlic (<i>Allium sativum</i>) on the Pharmacokinetics of Docetaxel. <i>Clinical Cancer Research</i> , 2006, 12, 4636-4640.	3.2	72
134	Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. <i>Cancer Research</i> , 2003, 63, 3189-94.	0.4	72
135	Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. <i>Anti-Cancer Drugs</i> , 2007, 18, 111-126.	0.7	71
136	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5038-5047.	3.2	70
137	Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates. <i>ELife</i> , 2019, 8, .	2.8	70
138	A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valsopodar (PSC 833) in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 4724-4733.	3.2	69
139	Thalidomide Analogues as Anticancer Drugs. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 167-174.	0.8	69
140	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4633-4641.	3.2	68
141	Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. <i>Cancer</i> , 1995, 76, 453-462.	2.0	67
142	Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. <i>Clinical Cancer Research</i> , 2006, 12, 4331-4338.	3.2	67
143	A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 7101-7106.	3.2	66
144	Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. <i>American Journal of Medicine</i> , 1988, 85, 452-453.	0.6	65

#	ARTICLE	IF	CITATIONS
145	Apoptosis: Its Role in the Development of Malignancies and its Potential as a Novel Therapeutic Target. <i>Annals of Pharmacotherapy</i> , 1997, 31, 76-82.	0.9	65
146	Taxane-Mediated Antiangiogenesis in Vitro. <i>Cancer Research</i> , 2004, 64, 821-824.	0.4	65
147	Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. <i>Therapeutics and Clinical Risk Management</i> , 2005, 1, 107-114.	0.9	65
148	Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 7398-7404.	3.2	64
149	Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 1496-1503.	3.2	64
150	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12703-12708.	3.3	64
151	An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5918-5926.	3.2	64
152	Suramin's development: what did we learn?. <i>Investigational New Drugs</i> , 2002, 20, 209-219.	1.2	63
153	TMPRSS2: Potential Biomarker for COVID-19 Outcomes. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 801-807.	1.0	63
154	Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. <i>American Journal of Cardiology</i> , 1995, 76, 1072-1073.	0.7	62
155	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 476-484.	0.6	62
156	Integrating pharmacogenetic information and clinical decision support into the electronic health record. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 522-528.	2.2	61
157	Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide. <i>Cancer Biology and Therapy</i> , 2002, 1, 669-673.	1.5	60
158	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. <i>BJU International</i> , 2008, 102, 617-621.	1.3	60
159	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , 2014, 155, 176-187.	1.4	60
160	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1099-1109.	5.1	59
161	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 209-226.	1.9	59
162	Reversal of Multidrug Resistance: Lessons from Clinical Oncology. <i>Novartis Foundation Symposium</i> , 0, , 83-102.	1.2	59

#	ARTICLE	IF	CITATIONS
163	Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 800-811.	0.8	58
164	Thalidomide Metabolites and Analogues. 3. Synthesis and Antiangiogenic Activity of the Teratogenic and TNF α -Modulatory Thalidomide Analogue 2-(2,6-Dioxopiperidine-3-yl)phthalimidine. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3793-3799.	2.9	58
165	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 299-307.	2.0	58
166	Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 362-367.	1.4	57
167	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1724-33.	3.3	57
168	Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. <i>Journal of Controlled Release</i> , 2017, 268, 147-158.	4.8	57
169	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 4499-4507.	3.2	55
170	Dual Targeting of the Androgen Receptor and Hypoxia-Inducible Factor 1 α Pathways Synergistically Inhibits Castration-Resistant Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2015, 87, 1006-1012.	1.0	55
171	A phase I study of TRC105 anti α endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 116, 546-555.	1.3	55
172	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750 α an antisense oligonucleotide against eIF4E α in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 1648-1657.	2.3	55
173	The effect of an adenosine A _{2A} agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. <i>Fluids and Barriers of the CNS</i> , 2018, 15, 2.	2.4	55
174	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 645-652.	1.1	54
175	Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1083-1090.	2.0	53
176	Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 650-660.	1.0	52
177	Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 368-373.	1.0	51
178	PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. <i>Oncologist</i> , 2021, 26, e115-e129.	1.9	51
179	Laparoscopic continuous hyperthermic peritoneal perfusion. No competing interests declared. <i>Journal of the American College of Surgeons</i> , 2001, 193, 225-229.	0.2	50
180	5 α -OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 104-110.	1.0	50

#	ARTICLE	IF	CITATIONS
181	Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice. <i>Clinical Cancer Research</i> , 2004, 10, 4192-4197.	3.2	50
182	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. <i>Clinical Cancer Research</i> , 2011, 17, 3388-3397.	3.2	49
183	Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. <i>Scientific Reports</i> , 2016, 6, 30038.	1.6	48
184	Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2219-2227.	2.9	47
185	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , 2010, 10, 511.	1.1	47
186	The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. <i>Clinical Cancer Research</i> , 2002, 8, 1242-50.	3.2	47
187	Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 796, 181-188.	1.2	46
188	Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1 α /p300 Interaction. <i>Journal of Natural Products</i> , 2016, 79, 1267-1275.	1.5	46
189	Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1397-1406.	3.2	46
190	Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer. <i>Cancer Investigation</i> , 1996, 14, 513-517.	0.6	45
191	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007, 99, 1047-1055.	1.3	45
192	Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 862, 213-218.	1.2	45
193	Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4292-4298.	3.2	45
194	A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 880, 132-139.	1.2	45
195	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 406-410.	2.0	45
196	Disclosing a Diagnosis of Cancer: Where and How Does It Occur?. <i>Journal of Clinical Oncology</i> , 2010, 28, 3630-3635.	0.8	44
197	<i>In vivo</i> screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. <i>Oncotarget</i> , 2016, 7, 33237-33245.	0.8	44
198	Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel. <i>Clinical Cancer Research</i> , 2013, 19, 3095-3104.	3.2	43

#	ARTICLE	IF	CITATIONS
199	Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened. <i>Journal of Urology</i> , 2014, 192, 379-384.	0.2	43
200	Synergistic targeted inhibition of <sc>MEK</sc> and dual <sc>PI</sc>3K/<sc>mTOR</sc> diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 643-655.	1.5	43
201	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 3333-3340.	3.9	43
202	A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 1995, 75, 2159-2164.	2.0	42
203	Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 206-215.	1.0	42
204	New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. <i>Angiogenesis</i> , 1997, 1, 23-35.	3.7	42
205	Approaches to preclinical screening of antiangiogenic agents. <i>Seminars in Oncology</i> , 2001, 28, 570-576.	0.8	42
206	Recent advances in pharmacogenetic approaches to anticancer drug development. <i>Drug Development Research</i> , 2004, 62, 233-253.	1.4	42
207	Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. <i>Cancer Causes and Control</i> , 2011, 22, 1121-1131.	0.8	42
208	Are sex discordant outcomes in COVID-19 related to sex hormones?. <i>Seminars in Oncology</i> , 2020, 47, 335-340.	0.8	42
209	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.	0.2	41
210	Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. <i>Discovery Medicine</i> , 2012, 13, 19-34.	0.5	41
211	Pharmacokinetic Studies with Recombinant Cytokines. <i>Clinical Pharmacokinetics</i> , 1997, 32, 368-381.	1.6	40
212	Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 394-401.	1.0	40
213	Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1369-1374.	0.9	40
214	Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1698-1705.	3.0	40
215	Phase <sc>II</sc> clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013, 111, 1269-1280.	1.3	40
216	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	0.9	40

#	ARTICLE	IF	CITATIONS
217	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 2326-2338.	3.9	40
218	Methods for extracting and amplifying genomic DNA isolated from frozen serum. <i>Nature Biotechnology</i> , 1998, 16, 91-94.	9.4	39
219	Augmentation of Melanoma-Specific Gene Expression Using a Tandem Melanocyte-Specific Enhancer Results in Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene in Melanoma. <i>Human Gene Therapy</i> , 1999, 10, 889-898.	1.4	39
220	Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 123, 686-694.	0.4	39
221	Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 275-281.	1.1	39
222	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. <i>Anti-Cancer Drugs</i> , 2018, 29, 457-465.	0.7	39
223	Androgen Receptor CAG Repeat Length and Association With Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. <i>Journal of Urology</i> , 2010, 184, 2297-2302.	0.2	38
224	Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. <i>Science Translational Medicine</i> , 2021, 13, eabd8077.	5.8	38
225	Synthesis of Racemic 5-Hydroxy-3-phthalimidoglutaramide. A Metabolite of Thalidomide Isolated from Human Plasma. <i>Journal of Organic Chemistry</i> , 2005, 70, 10117-10120.	1.7	37
226	Androgen receptor variation affects prostate cancer progression and drug resistance. <i>Pharmacological Research</i> , 2016, 114, 152-162.	3.1	37
227	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	2.5	37
228	EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINES. <i>Journal of Urology</i> , 2000, 163, 1022-1026.	0.2	36
229	A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. <i>United European Gastroenterology Journal</i> , 2015, 3, 453-461.	1.6	36
230	A facile scheme for phthalimide to phthalimidine conversion. <i>Tetrahedron Letters</i> , 1999, 40, 2087-2090.	0.7	35
231	Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. <i>Cancer Biology and Therapy</i> , 2008, 7, 1004-1005.	1.5	35
232	Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 13-18.	1.5	35
233	Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1. <i>Journal of the American Chemical Society</i> , 2015, 137, 5569-5575.	6.6	35
234	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 828-836.	3.2	35

#	ARTICLE	IF	CITATIONS
235	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
236	A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 579.	0.9	34
237	Angiogenesis inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 233-247.	0.9	34
238	Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1821-1831.	1.6	33
239	Bioluminescent imaging study. <i>Cancer Biology and Therapy</i> , 2010, 10, 38-43.	1.5	33
240	The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 708, 21-27.	0.4	33
241	Inhibition of the HIF1-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 509-516.	2.6	33
242	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. <i>JAMA Oncology</i> , 2018, 4, 1781.	3.4	33
243	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. <i>Blood</i> , 2020, 135, 2316-2319.	0.6	33
244	UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response. <i>Invasion & Metastasis</i> , 1998, 18, 209-218.	0.5	32
245	A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2010, 183, 2219-2226.	0.2	32
246	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 461-473.	1.0	32
247	Reviewing the role of healthy volunteer studies in drug development. <i>Journal of Translational Medicine</i> , 2018, 16, 336.	1.8	32
248	Phase I/IIb study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 79175-79187.	0.8	32
249	Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. <i>Cancer</i> , 2006, 106, 63-67.	2.0	31
250	Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1246-1250.	1.9	31
251	Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 62, 140-148.	1.4	31
252	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 865-873.	1.0	31

#	ARTICLE	IF	CITATIONS
253	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	1.0	31
254	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	2.0	31
255	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. <i>Oncotarget</i> , 2014, 5, 8161-8172.	0.8	31
256	Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. <i>Human Reproduction</i> , 2003, 18, 1820-1827.	0.4	30
257	Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 806, 305-310.	1.2	30
258	Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate Cancer. <i>Urology</i> , 2007, 70, 217-220.	0.5	30
259	Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. <i>Journal of Organic Chemistry</i> , 2016, 81, 10631-10640.	1.7	30
260	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1694-1704.	1.9	30
261	Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, S78-S84.	1.1	29
262	A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid [®]), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer. <i>Clinical Prostate Cancer</i> , 2004, 2, 241-243.	2.1	29
263	Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2012, 17, 312-320.	1.9	29
264	Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. <i>Cancer Causes and Control</i> , 2016, 27, 175-182.	0.8	29
265	Flavopiridol Inversely Affects p21WAF1/CIP1 and p53 and Protects p21-Sensitive Cells from Paclitaxel. <i>Cancer Biology and Therapy</i> , 2002, 1, 420-425.	1.5	28
266	Selective leukemic-cell killing by a novel functional class of thalidomide analogs. <i>Blood</i> , 2006, 108, 4126-4135.	0.6	28
267	Estrogen Receptor β and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E368-E372.	1.8	28
268	A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 714-723.	1.2	28
269	Insulin-Like Growth Factors and Insulin-Like Growth Factor- β Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2013, 6, 91-99.	0.7	28
270	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2228-2237.	1.9	28

#	ARTICLE	IF	CITATIONS
271	Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. <i>Anti-Cancer Drugs</i> , 2003, 14, 125-135.	0.7	27
272	Effects of Î±1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine. <i>Clinical Cancer Research</i> , 2004, 10, 6840-6846.	3.2	27
273	Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 605-611.	1.1	27
274	A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 383-389.	1.1	27
275	A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 154-161.	1.0	27
276	ANG1005 for breast cancer brain metastases: correlation between 18F-FLTâ€“PET after first cycle and MRI in response assessment. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 51-59.	1.1	27
277	Pharmacogenomics and histone deacetylase inhibitors. <i>Pharmacogenomics</i> , 2016, 17, 1807-1815.	0.6	27
278	Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>PLoS ONE</i> , 2015, 10, e0126672.	1.1	27
279	Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer. <i>Current Drug Metabolism</i> , 2003, 4, 505-513.	0.7	27
280	Acute renal toxicity associated with suramin in the treatment of prostate cancer. <i>Cancer</i> , 1994, 74, 1612-1614.	2.0	26
281	Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance. <i>PLoS ONE</i> , 2014, 9, e95532.	1.1	26
282	BET bromodomain inhibitorsâ€“A novel epigenetic approach in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1583-1585.	1.5	26
283	Phase I Trial of Bortezomib (PS-341; NSC 681239) and â€œNonhybridâ€“(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. <i>Clinical Cancer Research</i> , 2014, 20, 5652-5662.	3.2	26
284	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 704-716.	3.2	26
285	Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma. <i>Mayo Clinic Proceedings</i> , 1999, 74, 137-145.	1.4	25
286	Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. <i>Anti-Cancer Drugs</i> , 2008, 19, 275-281.	0.7	25
287	Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy. <i>Cancer Biology and Therapy</i> , 2013, 14, 90-91.	1.5	25
288	Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. <i>Clinical Cancer Research</i> , 2016, 22, 1197-1210.	3.2	25

#	ARTICLE	IF	CITATIONS
289	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	1.1	25
290	Lysyl oxidase (LOX) and hypoxia-induced metastases. <i>Cancer Biology and Therapy</i> , 2006, 5, 909-911.	1.5	24
291	Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. <i>Clinical Cancer Research</i> , 2003, 9, 562-70.	3.2	24
292	A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. <i>Analytica Chimica Acta</i> , 1997, 339, 91-97.	2.6	23
293	Histone deacetylase inhibitors are potent radiation protectants. <i>Cancer Biology and Therapy</i> , 2004, 3, 612-613.	1.5	23
294	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. <i>BJU International</i> , 2008, 101, 884-888.	1.3	23
295	Phase I trial of 7-hydroxystaurosporine and fludarabine phosphate: <i>in vivo</i> evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 2284-2292.	0.6	23
296	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 229-237.	0.9	23
297	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 590-597.	1.3	23
298	Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. <i>Cytokine</i> , 2018, 108, 213-224.	1.4	23
299	Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. <i>Molecular Pharmacology</i> , 2019, 96, 158-167.	1.0	23
300	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
301	Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. <i>American Journal of Hematology</i> , 2001, 67, 51-53.	2.0	22
302	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. <i>BJU International</i> , 2008, 102, 1694-1699.	1.3	22
303	The Role of MRI in Prostate Cancer Active Surveillance. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	22
304	A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 63-68.	1.4	22
305	Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 159-163.	0.7	22
306	Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat. <i>ChemMedChem</i> , 2021, 16, 2082-2088.	1.6	22

#	ARTICLE	IF	CITATIONS
307	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. <i>PLoS ONE</i> , 2016, 11, e0152007.	1.1	22
308	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285.	1.9	22
309	Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. <i>Biomedical Applications</i> , 2001, 759, 247-257.	1.7	21
310	Secondary hormonal therapy for prostate cancer: what lies on the horizon?. <i>BJU International</i> , 2008, 101, 271-274.	1.3	21
311	Sarcosine as a potential prostate cancer biomarker and therapeutic target. <i>Cancer Biology and Therapy</i> , 2010, 9, 341-342.	1.5	21
312	CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 123.	1.3	21
313	Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models. <i>Marine Drugs</i> , 2018, 16, 241.	2.2	21
314	Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors. <i>ChemMedChem</i> , 2020, 15, 270-273.	1.6	21
315	Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 845-54.	1.9	21
316	A Preliminary Risk-Benefit Assessment of Paclitaxel. <i>Drug Safety</i> , 1995, 12, 196-208.	1.4	20
317	High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 22, 1003-1014.	1.4	20
318	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003, 169, 357-360.	0.2	20
319	Small Molecule-Mediated Anti-Cancer Therapy via Hypoxia Inducible Factor-1 Blockade. <i>Cancer Biology and Therapy</i> , 2004, 3, 503-504.	1.5	20
320	Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. <i>Investigational New Drugs</i> , 2006, 24, 367-375.	1.2	20
321	ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 563-568.	0.7	20
322	Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. <i>Cancer</i> , 2016, 122, 2332-2340.	2.0	20
323	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. <i>Molecular Cancer Research</i> , 2017, 15, 1096-1105.	1.5	20
324	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017, 22, 505-e49.	1.9	20

#	ARTICLE	IF	CITATIONS
325	Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. <i>Methods in Molecular Biology</i> , 2014, 1175, 91-120.	0.4	20
326	Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography–mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 811, 135-141.	1.2	20
327	Treatment options for androgen-independent prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 49-57.	0.3	20
328	The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. , 1996, 29, 177-182.		19
329	Initial Pharmacokinetics and Bioavailability of PSC 833, a P-glycoprotein Antagonist. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 123-128.	1.0	19
330	A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer. <i>Urologia Internationalis</i> , 1999, 63, 120-125.	0.6	19
331	The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2003, 2, 153-159.	2.1	19
332	Mechanisms of Disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. <i>Nature Reviews Urology</i> , 2005, 2, 101-107.	1.4	19
333	Importance of the Stress Kinase p38 in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells. <i>Clinical Cancer Research</i> , 2006, 12, 3502-3509.	3.2	19
334	Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience. <i>Cancer Prevention Research</i> , 2010, 3, 1523-1533.	0.7	19
335	Impact of <i>ABCB1</i> Allelic Variants on QTc Interval Prolongation. <i>Clinical Cancer Research</i> , 2011, 17, 937-946.	3.2	19
336	Prostate cancer progression attributed to autonomic nerve development. <i>Cancer Biology and Therapy</i> , 2013, 14, 1005-1006.	1.5	19
337	UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 450-460.	1.0	19
338	Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S67-S77.	1.0	19
339	Mifepristone: Antineoplastic Studies. <i>Clinical Obstetrics and Gynecology</i> , 1996, 39, 498-505.	0.6	19
340	Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. <i>Anticancer Research</i> , 2003, 23, 3585-90.	0.5	19
341	A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer. <i>Acta Oncologica</i> , 2003, 42, 195-201.	0.8	18
342	Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1709-1717.	0.9	18

#	ARTICLE	IF	CITATIONS
343	A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application. <i>Chromatography (Basel)</i> , 2014, 1, 82-95.	1.2	18
344	<p>Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 991-1003.	3.3	18
345	The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer. <i>Urologia Internationalis</i> , 2002, 68, 16-23.	0.6	17
346	Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 806, 289-293.	1.2	17
347	Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. <i>Prostate</i> , 2010, 70, 584-590.	1.2	17
348	Monitor tumor burden with circulating tumor DNA. <i>Cancer Biology and Therapy</i> , 2013, 14, 697-698.	1.5	17
349	Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. <i>Pediatric Blood and Cancer</i> , 2015, 62, 603-610.	0.8	17
350	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 4238-4247.	3.2	17
351	ETS-TMPRSS2 fusion gene products in prostate cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 254-255.	1.5	16
352	Hormone-Refractory Prostate Cancer. <i>Drugs</i> , 2007, 67, 1109-1124.	4.9	16
353	The Genetics of Castration-Resistant Prostate Cancer: What Can the Germline Tell Us?. <i>Clinical Cancer Research</i> , 2008, 14, 4691-4693.	3.2	16
354	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e25-31.e33.	0.8	16
355	Evaluation of entinostat alone and in combination with standard care cytotoxic agents against rhabdomyosarcoma xenograft models. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27820.	0.8	16
356	Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 438-451.	1.3	16
357	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1171, 122641.	1.2	16
358	The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. <i>Translational Cancer Research</i> , 2016, 5, S1107-S1110.	0.4	16
359	In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. <i>Cancer Letters</i> , 1997, 113, 111-116.	3.2	15
360	Pharmacy Education: Back to the Basics?. <i>Pharmacotherapy</i> , 2003, 23, 1381-1390.	1.2	15

#	ARTICLE	IF	CITATIONS
361	Immunomodulation of multiple myeloma. <i>Cancer Biology and Therapy</i> , 2004, 3, 1060-1061.	1.5	15
362	Angiogenesis and prostate cancer: Important laboratory and clinical findings. <i>Current Oncology Reports</i> , 2005, 7, 215-219.	1.8	15
363	Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. <i>European Urology</i> , 2007, 52, 1020-1027.	0.9	15
364	Development and Validation of an LC-MS Assay for Finasteride and its Application to Prostate Cancer Prevention Trial Sample Analysis. <i>Journal of Chromatographic Science</i> , 2008, 46, 356-361.	0.7	15
365	More than an accessory: implications of type III transforming growth factor β receptor loss in prostate cancer. <i>BJU International</i> , 2010, 105, 913-916.	1.3	15
366	Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1586-1587.	1.5	15
367	A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 955-967.	1.1	15
368	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 446-456.	3.3	15
369	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. <i>Blood</i> , 2021, 137, 896-907.	0.6	15
370	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , 2021, 27, 3298-3306.	3.2	15
371	Plasma Protein Binding of Phenylacetate and Phenylbutyrate, Two Novel Antineoplastic Agents. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 714-720.	1.0	15
372	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. <i>Biomedical Chromatography</i> , 2000, 14, 338-343.	0.8	14
373	Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. <i>Cancer Biology and Therapy</i> , 2004, 3, 719-720.	1.5	14
374	Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. <i>World Journal of Urology</i> , 2004, 22, 425-430.	1.2	14
375	Associations of Serum Sex Steroid Hormone and 5 α -Androstane-3 β ,17 β -Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1823-1832.	1.1	14
376	Bcl-2 Family of Proteins as Therapeutic Targets in Genitourinary Neoplasms. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 10-19.	0.9	14
377	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimides for nitrite, TNF- α and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1547-1559.	1.4	14
378	Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>Carcinogenesis</i> , 2018, 39, 125-133.	1.3	14

#	ARTICLE	IF	CITATIONS
379	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2308-2318.	1.9	14
380	Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer. <i>Southern Medical Journal</i> , 2015, 108, 224-228.	0.3	14
381	Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2014, 19, 16-24.	0.3	14
382	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 532-540.	1.0	14
383	Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)- β -hydroxyglutamic acid. <i>Tetrahedron Letters</i> , 2000, 41, 2275-2278.	0.7	13
384	Phase I Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura. <i>Clinical Lung Cancer</i> , 2002, 4, 186-192.	1.1	13
385	Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 215-229.	2.4	13
386	Genotyping and functional analysis of the D104N variant of human endostatin. <i>Cancer Biology and Therapy</i> , 2004, 3, 1298-1303.	1.5	13
387	Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 804, 289-294.	1.2	13
388	Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. <i>Urology</i> , 2005, 66, 571-576.	0.5	13
389	The use of thalidomide in androgen-independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 246-249.	0.8	13
390	Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 865, 153-158.	1.2	13
391	CHIP and gp78-mediated ubiquitination of CYP3A4. <i>Cancer Biology and Therapy</i> , 2011, 11, 549-551.	1.5	13
392	UGT genotyping in belinostat dosing. <i>Pharmacological Research</i> , 2016, 105, 22-27.	3.1	13
393	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 247-257.	1.3	13
394	Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. <i>FASEB Journal</i> , 2020, 34, 11395-11404.	0.2	13
395	Stem cell clinics: risk of proliferation. <i>Lancet Oncology</i> , The, 2020, 21, 205-206.	5.1	13
396	Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 915-924.	1.9	13

#	ARTICLE	IF	CITATIONS
397	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. <i>Cancers</i> , 2021, 13, 2154.	1.7	13
398	Phase I/IIb study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. <i>Oncotarget</i> , 2019, 10, 2855-2868.	0.8	13
399	Lutetium-177-PSMA-617: A Vision of the Future. <i>Cancer Biology and Therapy</i> , 2022, 23, 186-190.	1.5	13
400	Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1124-1135.	1.0	12
401	Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of Taxol [®] and Paxene [®] . <i>Cancer Biology and Therapy</i> , 2005, 4, 555-560.	1.5	12
402	Combinatorial Antileukemic Disruption of Oxidative Homeostasis and Mitochondrial Stability by the Redox Reactive Thalidomide 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1 <i>H</i> -isoindole-1,3(2 <i>H</i>)-dione (CPS49) and Flavopiridol. <i>Molecular Pharmacology</i> , 2008, 74, 872-883.	1.0	12
403	Angiogenesis inhibitors increase tumor stem cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 586-587.	1.5	12
404	Urinary <i>α</i> -HGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. <i>Biomarkers in Medicine</i> , 2013, 7, 831-841.	0.6	12
405	Epigenetic approaches to overcoming chemotherapy resistance. <i>Lancet Oncology</i> , The, 2015, 16, 1013-1015.	5.1	12
406	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
407	Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. <i>Journal of Neuro-Oncology</i> , 2017, 132, 401-407.	1.4	12
408	Precision medicine applications in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	12
409	PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. <i>Journal of Controlled Release</i> , 2019, 308, 86-97.	4.8	12
410	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113073.	1.4	12
411	Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures. <i>Molecular Cancer Research</i> , 2020, 18, 1278-1289.	1.5	12
412	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. <i>JAMA Oncology</i> , 2021, 7, 1678.	3.4	12
413	Vertical Inhibition of the RAF ^Δ “MEK ^Δ “ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRASQ61X</i> Mutant Rhabdomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 170-183.	1.9	12
414	Peripheral Neuropathy in HIV Patient after Isoniazid Therapy Initiated. <i>DICP: the Annals of Pharmacotherapy</i> , 1991, 25, 100-101.	0.2	11

#	ARTICLE	IF	CITATIONS
415	Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. <i>Tetrahedron Letters</i> , 2000, 41, 7151-7155.	0.7	11
416	Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 509-510.	2.3	11
417	Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapy. <i>Cancer Biology and Therapy</i> , 2004, 3, 1212-1213.	1.5	11
418	Cyclooxygenase-2 and angiogenesis in prostate cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 813-814.	1.5	11
419	The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-8.	1.6	11
420	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2017, 58, 639-645.	0.6	11
421	Vertebrate embryos as tools for anti-angiogenic drug screening and function. <i>Reproductive Toxicology</i> , 2017, 70, 49-59.	1.3	11
422	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. <i>Molecules</i> , 2020, 25, 5683.	1.7	11
423	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 258-267.e1.	0.9	11
424	On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 67-72.	1.0	11
425	Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. <i>Cancer Treatment Reviews</i> , 1996, 22, 105-118.	3.4	10
426	Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer. <i>Acta Oncologica</i> , 1996, 35, 763-765.	0.8	10
427	Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one. , 1996, 51, 152-157.		10
428	Antiangiogenesis: A Possible Treatment Option for Prostate Cancer?. <i>Clinical Genitourinary Cancer</i> , 2005, 4, 197-202.	0.9	10
429	Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. <i>Anti-Cancer Drugs</i> , 2006, 17, 977-983.	0.7	10
430	Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine. <i>Clinical Cancer Research</i> , 2014, 20, 2525-2529.	3.2	10
431	Synthesis of a stable and orally bioavailable englerin analogue. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2641-2644.	1.0	10
432	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. <i>Cancer Biology and Therapy</i> , 2020, 21, 223-230.	1.5	10

#	ARTICLE	IF	CITATIONS
433	Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 827-830.	1.1	10
434	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 475-486.	1.1	10
435	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. <i>Cancer Research</i> , 2021, 81, 1076-1086.	0.4	10
436	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. <i>Oncologist</i> , 2021, 26, 288-e541.	1.9	10
437	Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. <i>Scientific Reports</i> , 2021, 11, 10765.	1.6	10
438	Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model. <i>Molecular Cancer Research</i> , 2021, 19, 2081-2095.	1.5	10
439	Determination of fraction unbound docetaxel using microequilibrium dialysis. <i>Analytical Biochemistry</i> , 2004, 331, 192-194.	1.1	10
440	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. <i>Blood</i> , 2020, 136, 43-45.	0.6	10
441	Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. <i>Blood</i> , 2008, 112, 1568-1568.	0.6	10
442	Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. <i>Blood</i> , 2014, 124, 2105-2105.	0.6	10
443	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 1353-1362.	3.2	10
444	The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 1-8.	2.3	9
445	Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 830, 35-40.	1.2	9
446	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. <i>International Journal of Cancer</i> , 2009, 125, 1143-1146.	2.3	9
447	A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 927, 142-146.	1.2	9
448	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1014-1018.	1.5	9
449	Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids. <i>ChemMedChem</i> , 2016, 11, 2621-2629.	1.6	9
450	The canSAR data hub for drug discovery. <i>Lancet Oncology</i> , The, 2016, 17, 286.	5.1	9

#	ARTICLE	IF	CITATIONS
451	Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 165-175.	1.1	9
452	Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 521-536.	0.8	9
453	A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1086, 56-62.	1.2	9
454	Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1003-1007.	1.1	9
455	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
456	Checkpoint inhibitor immunotherapy during pregnancy for relapsed refractory Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2022, 97, 833-838.	2.0	9
457	National Cancer Institute Intramural Approach to Advanced Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2002, 1, 153-162.	2.1	8
458	A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. <i>Biomedical Chromatography</i> , 2002, 16, 379-382.	0.8	8
459	Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. <i>Cancer Biology and Therapy</i> , 2008, 7, 412-415.	1.5	8
460	A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. <i>Cancer Biology and Therapy</i> , 2009, 8, 1800-1805.	1.5	8
461	Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. <i>American Journal of Therapeutics</i> , 2010, 17, 176-181.	0.5	8
462	A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting. <i>Cancer Biology and Therapy</i> , 2010, 9, 583-584.	1.5	8
463	Reply to Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4820.	3.3	8
464	Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease. <i>Urology</i> , 2015, 85, 616-620.	0.5	8
465	Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. <i>Separations</i> , 2016, 3, 4.	1.1	8
466	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. <i>Clinical and Translational Oncology</i> , 2016, 18, 653-659.	1.2	8
467	Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors. <i>MedChemComm</i> , 2019, 10, 500-504.	3.5	8
468	Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?. <i>Cancer Biology and Therapy</i> , 2020, 21, 1-3.	1.5	8

#	ARTICLE	IF	CITATIONS
469	Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1558-1569.	2.3	8
470	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15786-e15786.	0.8	8
471	Ibrutinib's off-target mechanism: cause for dose optimization. <i>Cancer Biology and Therapy</i> , 2021, 22, 529-531.	1.5	8
472	Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. <i>Endocrine-Related Cancer</i> , 2022, 29, 99-109.	1.6	8
473	A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1994, 17, 2895-2900.	0.9	7
474	In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. <i>Anti-Cancer Drugs</i> , 1994, 5, 336-342.	0.7	7
475	PHARMACOKINETICS OF ELEMENTAL PLATINUM (ULTRAFILTRATE AND TOTAL) AFTER A THIRTY MINUTE INTRAVENOUS INFUSION OF ORMAPLATIN. , 1997, 18, 347-359.		7
476	Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 673-687.	0.6	7
477	The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. <i>Oncology Issues</i> , 2000, 15, 23-27.	0.0	7
478	Mutations in the EGFR: The Importance of Genotyping. <i>Cancer Biology and Therapy</i> , 2004, 3, 434-435.	1.5	7
479	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. <i>BJU International</i> , 2007, 99, 525-528.	1.3	7
480	Extraction of DNA from Serum for High-Throughput Genotyping: Findings from Pilot Studies Within the Prostate Cancer Prevention Trial. <i>Urology</i> , 2008, 71, 967-970.	0.5	7
481	Cabazitaxel. <i>Cancer Biology and Therapy</i> , 2010, 10, 1233-1234.	1.5	7
482	Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?. <i>BMJ Open</i> , 2013, 3, e002030.	0.8	7
483	Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 970, 95-101.	1.2	7
484	Revisiting 5 α -reductase inhibitors and the risk of prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 400-401.	1.9	7
485	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. <i>Prostate</i> , 2020, 80, 336-344.	1.2	7
486	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 435-444.	1.3	7

#	ARTICLE	IF	CITATIONS
487	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 176-176.	0.8	7
488	A Chiral Pool Approach toward the Synthesis of Thalidomide Metabolites. <i>Heterocycles</i> , 2006, 70, 321.	0.4	7
489	Leptomeningeal Carcinomatosis in Metastatic Prostate Cancer. <i>Southern Medical Journal</i> , 2002, 95, 107.	0.3	6
490	Antiangiogenesis therapeutic strategies in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2002, 21, 93-106.	2.7	6
491	Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 809, 81-86.	1.2	6
492	Randomized discontinuation trial of sorafenib (BAY 43-9006). <i>Cancer Biology and Therapy</i> , 2006, 5, 1270-1272.	1.5	6
493	Uncovering the genetic landscape driving castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2013, 14, 399-400.	1.5	6
494	Androgen Receptor CAG Repeat Length and \hat{A} TMPRSS2:ETS Prostate Cancer Risk: \hat{A} Results From the Prostate Cancer Prevention Trial. <i>Urology</i> , 2014, 84, 127-131.	0.5	6
495	Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. <i>Pharmacogenomics</i> , 2016, 17, 1979-1986.	0.6	6
496	Cellular identity crisis: Antiandrogen resistance by lineage plasticity. <i>Cancer Biology and Therapy</i> , 2017, 18, 841-842.	1.5	6
497	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 565-570.	1.1	6
498	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019, 14, e0212097.	1.1	6
499	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. <i>Journal of Human Genetics</i> , 2019, 64, 545-550.	1.1	6
500	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) _n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 896.	1.8	6
501	Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa005.	0.4	6
502	Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.. <i>Blood</i> , 2006, 108, 2469-2469.	0.6	6
503	Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study. <i>Blood</i> , 2014, 124, 4746-4746.	0.6	6
504	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-314.	0.8	6

#	ARTICLE	IF	CITATIONS
505	A modeling and simulation study of less frequent dosing of nivolumab 480 mg.. Journal of Clinical Oncology, 2019, 37, 3115-3115.	0.8	6
506	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology, 2020, 38, 105-105.	0.8	6
507	Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 331-344.	0.3	5
508	The role of drug-metabolising enzymes in clinical responses to chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 17-25.	1.5	5
509	Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 302-306.	1.2	5
510	Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 355-359.	1.2	5
511	Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide. Clinical Genitourinary Cancer, 2009, 7, E37-E38.	0.9	5
512	Prostate cancer genomic signature offers prognostic value. Cancer Biology and Therapy, 2010, 10, 1079-1080.	1.5	5
513	Significant addition to treatment options for bone metastasis in prostate cancer. Cancer Biology and Therapy, 2012, 13, 69-70.	1.5	5
514	How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer. Cancer Biology and Therapy, 2012, 13, 1141-1142.	1.5	5
515	Multiparametric Magnetic Resonance Imaging of the Prostate Aids to Detect Lesion Progression. Journal of Computer Assisted Tomography, 2014, 38, 565-567.	0.5	5
516	Effect of 5 α -Reductase Inhibitor Use on Mortality From Prostate Cancer. JAMA Oncology, 2015, 1, 321.	3.4	5
517	Targeted PI3K γ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. Cancer Biology and Therapy, 2015, 16, 204-206.	1.5	5
518	Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?. Cancer Biology and Therapy, 2016, 17, 467-469.	1.5	5
519	<sc>CPS</sc>49 α -induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos. Journal of Anatomy, 2018, 232, 568-574.	0.9	5
520	Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides. ChemMedChem, 2018, 13, 2080-2089.	1.6	5
521	A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy. Pharmaceutics, 2021, 13, 997.	2.0	5
522	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	5

#	ARTICLE	IF	CITATIONS
523	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.. Journal of Clinical Oncology, 2020, 38, 11540-11540.	0.8	5
524	Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. Oncology Reports, 2006, 15, 519-24.	1.2	5
525	Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis. Cancer Biology and Therapy, 2008, 7, 1386-1387.	1.5	4
526	Androgen receptor sequence and variations in several common prostate cancer cell lines. Cancer Biology and Therapy, 2010, 9, 383-388.	1.5	4
527	Loss of OATP1B3 function causes Rotor syndrome. Cancer Biology and Therapy, 2012, 13, 1374-1375.	1.5	4
528	Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Investigational New Drugs, 2012, 30, 90-97.	1.2	4
529	Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biology and Therapy, 2014, 15, 1296-1298.	1.5	4
530	Evaluating immune responses after sipuleucel-T therapy. Cancer Biology and Therapy, 2015, 16, 1119-1121.	1.5	4
531	Building a hit list for the fight against metastatic castration resistant prostate cancer. Cancer Biology and Therapy, 2016, 17, 231-232.	1.5	4
532	Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. American Journal of Kidney Diseases, 2017, 69, 553-554.	2.1	4
533	Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. Cancer Biology and Therapy, 2017, 18, 470-472.	1.5	4
534	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 759-770.	1.1	4
535	Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 19-22.	0.2	4
536	Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in <i>DPYD</i> . Pharmacogenomics, 2021, 22, 81-85.	0.6	4
537	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. Blood, 2016, 128, 4527-4527.	0.6	4
538	Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.. Journal of Clinical Oncology, 2012, 30, 64-64.	0.8	4
539	Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis. Journal of Pediatric Pharmacology and Therapeutics, 2018, 23, 106-110.	0.3	4
540	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclox-induced cytotoxicity in atypical teratoid/rhabdoid tumors. Cell Death and Disease, 2022, 13, 410.	2.7	4

#	ARTICLE	IF	CITATIONS
541	An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC. <i>Analytical Letters</i> , 1997, 30, 2009-2021.	1.0	3
542	Piecing together the HIF-1 puzzle: The role of the CTGF as a molecular mechanism of HIF-1 regulation. <i>Cancer Biology and Therapy</i> , 2006, 5, 1443-1444.	1.5	3
543	Genetic stability of tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2008, 7, 331-332.	1.5	3
544	shRNA technology: Investigating Ras-dependent cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 1798-1799.	1.5	3
545	Survivin Is Not Induced by Novel Taxanes. <i>Molecular Pharmaceutics</i> , 2010, 7, 2216-2223.	2.3	3
546	Prolonged low intensity EPOCHâ€“rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 1117-1119.	1.5	3
547	Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation. <i>Cancer Biology and Therapy</i> , 2014, 15, 1293-1295.	1.5	3
548	Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?. <i>Cancer Biology and Therapy</i> , 2015, 16, 19-20.	1.5	3
549	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 217-221.	1.1	3
550	Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics. <i>Cancer Biology and Therapy</i> , 2018, 19, 953-955.	1.5	3
551	Antineoplastons: when is enough enough?. <i>Lancet Oncology, The</i> , 2018, 19, 733-734.	5.1	3
552	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. <i>Scientific Reports</i> , 2019, 9, 14884.	1.6	3
553	Insulin potentiation therapy for cancer?. <i>Lancet Oncology, The</i> , 2019, 20, 191-192.	5.1	3
554	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. <i>Vox Sanguinis</i> , 2021, 116, 141-154.	0.7	3
555	Facebook groups for alternative treatments for cancer: advertising masquerading as community support. <i>Lancet Oncology, The</i> , 2021, 22, 25-26.	5.1	3
556	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4599-TPS4599.	0.8	3
557	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreaticobiliary cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3051-3051.	0.8	3
558	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5096-TPS5096.	0.8	3

#	ARTICLE	IF	CITATIONS
559	The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?. <i>Lancet Oncology</i> , The, 2021, 22, 915-916.	5.1	3
560	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	0.8	3
561	Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.. <i>Blood</i> , 2005, 106, 1102-1102.	0.6	3
562	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11552-11552.	0.8	3
563	Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 553-563.	0.9	3
564	Alemtuzumab clearance, lymphocyte count, and Tâ€cell chimerism after hematopoietic stem cell transplant in sickle cell disease. <i>Pharmacotherapy</i> , 2022, 42, 14-22.	1.2	3
565	Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. <i>Blood</i> , 2019, 134, 4096-4096.	0.6	3
566	Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques (<i>Macaca mulatta</i>) Based on the Pharmacokinetics of Intrathecally Administered Inulin. <i>Comparative Medicine</i> , 2020, 70, 526-531.	0.4	3
567	Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. <i>Anticancer Research</i> , 2012, 32, 2391-8.	0.5	3
568	Dose Optimization of Pembrolizumab: Less May Be More. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 993-993.	2.3	3
569	Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome. <i>Cancer Biology and Therapy</i> , 2022, 23, 136-138.	1.5	3
570	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 93-93.	0.8	3
571	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	1.9	3
572	Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report. <i>Prostate Journal</i> , 1999, 1, 99-102.	0.2	2
573	hTert-Immortalized Endothelial Cells: An Important New Research Tool. <i>Cell Cycle</i> , 2004, 3, 787-787.	1.3	2
574	Upregulation of the Androgen Receptor during Prostate Cancer Progression. <i>Cancer Biology and Therapy</i> , 2004, 3, 284-285.	1.5	2
575	The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. <i>Cancer Biology and Therapy</i> , 2006, 5, 1094-1095.	1.5	2
576	Private Practice Administrative Costs Influenced by Insurance Payer Mix. <i>Journal of Oncology Practice</i> , 2009, 5, 291-297.	2.5	2

#	ARTICLE	IF	CITATIONS
577	Genetic variant associated with aggressive not indolent prostate cancer. <i>Cancer Biology and Therapy</i> , 2010, 9, 957-958.	1.5	2
578	Androgen synthesis and steroid transporters in prostate cancer: Rethinking the transition to CRPC. <i>Cancer Biology and Therapy</i> , 2010, 9, 1043-1045.	1.5	2
579	Reply to C. Nabhan et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e147-e147.	0.8	2
580	Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 237-238.	1.5	2
581	The androgen receptor transcriptional program in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 16-18.	1.5	2
582	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 215-218.	1.1	2
583	Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients. <i>Cancer Biology and Therapy</i> , 2017, 18, 545-546.	1.5	2
584	Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance. <i>Cancer Biology and Therapy</i> , 2018, 19, 869-870.	1.5	2
585	Local and Systemic Antitumor Effects of Photoactivatable Paclitaxel Prodrug on Rat Breast Tumor Models. <i>Photochemistry and Photobiology</i> , 2020, 96, 668-679.	1.3	2
586	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2020, 21, 884-887.	1.5	2
587	Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. <i>Scientific Reports</i> , 2021, 11, 5662.	1.6	2
588	Study to Compare Capsule and Liquid Formulations of Enzalutamide After <sc>Single-Dose</sc> Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , 2021, 26, 729-e1493.	1.9	2
589	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. <i>Blood</i> , 2018, 132, 1957-1957.	0.6	2
590	A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 117-117.	0.8	2
591	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10588-10588.	0.8	2
592	A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 173-173.	0.8	2
593	Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 241-241.	0.8	2
594	Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 130-130.	0.8	2

#	ARTICLE	IF	CITATIONS
595	Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 135-140.	1.2	1
596	Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics. <i>Cancer Biology and Therapy</i> , 2006, 5, 840-841.	1.5	1
597	Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 223-229.	0.2	1
598	Temporal-Mediated FGFR1 independence: Implications for targeting candidate molecules in prostate cancer. <i>Cancer Biology and Therapy</i> , 2008, 7, 1180-1181.	1.5	1
599	A genomic strategy for predicting androgen receptor activity in prostate tumors. <i>Cancer Biology and Therapy</i> , 2009, 8, 2002-2003.	1.5	1
600	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3187-3192.	1.2	1
601	Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism. <i>Cancer Biology and Therapy</i> , 2010, 9, 163-165.	1.5	1
602	Aflibercept in Pediatric Solid Tumors: Moving Beyond the Trap. <i>Clinical Cancer Research</i> , 2012, 18, 4868-4871.	3.2	1
603	Preformulation Study of NSC-726796. <i>AAPS PharmSciTech</i> , 2012, 13, 661-673.	1.5	1
604	A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 942-943, 107-112.	1.2	1
605	New mechanism of lenalidomide activity. <i>Cancer Biology and Therapy</i> , 2014, 15, 968-969.	1.5	1
606	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 203-204.	1.5	1
607	Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier. <i>Clinical Cancer Research</i> , 2017, 23, 7437-7439.	3.2	1
608	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , 2018, 19, 97-100.	1.5	1
609	Alam K et al. (2018) <i>Drug Metabolism Letters</i> ; 12, 24-32.. <i>Drug Metabolism Letters</i> , 2018, 12, 153-153.	0.5	1
610	Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?. <i>BJU International</i> , 2019, 124, 549-550.	1.3	1
611	Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1711-1716.	1.3	1
612	Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa. <i>AIDS Reviews</i> , 2021, 23, 13-27.	0.5	1

#	ARTICLE	IF	CITATIONS
613	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 2021, 39, e17044-e17044.	0.8	1
614	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. , 2000, 14, 338.		1
615	Whole or Partial Vessel Outgrowth Assays. , 0, , 105-121.		1
616	Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 2080-2080.	0.6	1
617	Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study. Blood. 2016. 128. 3339-3339.	0.6	1
618	Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft.. Journal of Clinical Oncology, 2012, 30, 4671-4671.	0.8	1
619	Androgen receptor and HIF-1 α interaction in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 197-197.	0.8	1
620	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. Journal of Clinical Oncology, 2013, 31, 128-128.	0.8	1
621	A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, TPS5095-TPS5095.	0.8	1
622	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 4543-4543.	0.8	1
623	Percutaneous hepatic perfusion with melphalan for unresectable liver metastasis. Hepatoma Research, 2016, 2, 197.	0.6	1
624	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.. Journal of Clinical Oncology, 2020, 38, 3553-3553.	0.8	1
625	Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 189-193.	0.4	1
626	Single whole genome sequencing analysis blazes the trail for precision medicine. Cancer Biology and Therapy, 2022, 23, 134-135.	1.5	1
627	Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted. Cancers, 2022, 14, 1131.	1.7	1
628	Subcutaneous Atezolizumab: A Jab Without a Benefit. Clinical Pharmacology in Drug Development, 2022, 11, 134-135.	0.8	1
629	Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.. Journal of Clinical Oncology, 2022, 40, e17033-e17033.	0.8	1
630	Nitrate Tolerance: Does Tid Isosorbide Dinitrate Mean Dosing Every Eight Hours?. DICP: the Annals of Pharmacotherapy, 1991, 25, 1272-1273.	0.2	0

#	ARTICLE	IF	CITATIONS
631	Epidemiology of drug interactions in cancer patients. <i>Nature Reviews Cancer</i> , 2006, 6, 824-824.	12.8	0
632	Assessing Progress Against Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 102-103.	0.9	0
633	DNA microarrays: Tissue removal and processing affects gene expression. <i>Cancer Biology and Therapy</i> , 2006, 5, 1608-1609.	1.5	0
634	Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients. <i>Cancer Biology and Therapy</i> , 2007, 6, 318-319.	1.5	0
635	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. <i>BJU International</i> , 2007, 100, 1245-1248.	1.3	0
636	PD-0020 Pharmacokinetic Analysis of Percutaneous Hepatic Perfusion (PHP) of Melphalan in Patients with Hepatic Metastases from Melanoma. <i>Annals of Oncology</i> , 2012, 23, iv25-iv26.	0.6	0
637	Challenges in overcoming hormonal resistance in prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 153-162.	0.0	0
638	New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1702-1703.	1.5	0
639	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 201-203.	1.5	0
640	Gene expression analysis enables repositioning of mithramycin for precision medicine inhibition of cancer stem cell signaling in thoracic malignancies. <i>Journal of the American College of Surgeons</i> , 2015, 221, e128-e129.	0.2	0
641	YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?. <i>Cancer Biology and Therapy</i> , 2016, 17, 592-594.	1.5	0
642	Resisting resistance: Establishing new treatment options for CRPC patients. <i>Cancer Biology and Therapy</i> , 2016, 17, 337-338.	1.5	0
643	A new predictive tool for postoperative radiotherapy in prostate cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 277-278.	1.5	0
644	Mapping a path for cancer precision medicine. <i>Lancet Oncology</i> , The, 2017, 18, 1444.	5.1	0
645	A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 132, 223-226.	1.4	0
646	How do you take your coffee?. <i>Lancet Oncology</i> , The, 2019, 20, 913-914.	5.1	0
647	Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. <i>Cancer Biology and Therapy</i> , 2020, 21, 782-784.	1.5	0
648	A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5090-TPS5090.	0.8	0

#	ARTICLE	IF	CITATIONS
649	Anti-Myeloma Activity of Two Novel N-Substituted and Tetrafluorinated Thalidomide Analogues.. Blood, 2004, 104, 2406-2406.	0.6	0
650	Association between variants on 8q24 and prostate cancer: A review and meta-analysis.. Journal of Clinical Oncology, 2012, 30, 28-28.	0.8	0
651	Effect of thalidomide on the TGF β -1-mediated synthesis of testosterone from DHEA in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 141-141.	0.8	0
652	Disruption of the HIF α /p300 interaction as a means of inhibiting angiogenesis. FASEB Journal, 2012, 26, 613.3.	0.2	0
653	Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients.. Journal of Clinical Oncology, 2012, 30, 3042-3042.	0.8	0
654	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. Journal of Clinical Oncology, 2014, 32, 211-211.	0.8	0
655	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 218-218.	0.8	0
656	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5074-5074.	0.8	0
657	Development of a CYP1B1*3 genotyping assay and mechanism of action studies related to docetaxel treatment in CRPC.. Journal of Clinical Oncology, 2014, 32, e16036-e16036.	0.8	0
658	Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects. Blood, 2014, 124, 3476-3476.	0.6	0
659	Tremelimumab: A monoclonal antibody against CTLA-4 in combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. Journal of Clinical Oncology, 2017, 35, 88-88.	0.8	0
660	A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.. Journal of Clinical Oncology, 2018, 36, TPS11586-TPS11586.	0.8	0
661	Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.. Journal of Clinical Oncology, 2019, 37, e16554-e16554.	0.8	0
662	BETting on next-generation bromodomain inhibitors. American Journal of Clinical and Experimental Urology, 2020, 8, 129-132.	0.4	0
663	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. Blood, 2021, 138, 2457-2457.	0.6	0
664	Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2021, 138, 1815-1815.	0.6	0
665	Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2020, 136, 18-19.	0.6	0
666	Prostate cancer - 6th International Congress. IDrugs: the Investigational Drugs Journal, 2006, 9, 675-8.	0.7	0

#	ARTICLE	IF	CITATIONS
667	OP059: Clinical impact of a targeted pharmacogenomic assessment within a cohort of individuals with suspected inborn errors of immunity. <i>Genetics in Medicine</i> , 2022, 24, S385.	1.1	0
668	Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 213, 114685.	1.4	0
669	HIF-prolyl-hydroxylase 2 clinical inhibitor complex structure and XChem fragment-based screen obtained with succinate co-product used as a crystallisation tool. <i>Acta Crystallographica Section A: Foundations and Advances</i> , 2021, 77, C1193-C1193.	0.0	0
670	PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e17046-e17046.	0.8	0